

**Mouse (monoclonal)  
Anti-cdk4  
Unconjugated  
PRODUCT ANALYSIS SHEET**

<b>Catalog Number:</b>	AHZ0202
<b>Lot Number:</b>	See product label
<b>Quantity/Volume:</b>	100 µg/0.5 mL
<b>Clone Number:</b>	DCS-31
<b>Isotype:</b>	IgG1 (mouse)
<b>Form of Antibody:</b>	Purified immunoglobulin in 10mM phosphate buffered saline, pH 7.4, with 0.2% bovine serum albumin.
<b>Preservation:</b>	0.09% sodium azide (Caution: sodium azide is a poisonous and hazardous substance. Handle with care and dispose of properly.)
<b>Purification:</b>	Purified from ascites by Protein G affinity chromatography.
<b>Immunogen:</b>	Purified recombinant cdk4 protein.
<b>Specificity:</b>	This antibody recognizes a protein of 34 kDa, identified as cyclin-dependent kinase-4 (cdk4, also known as p34 <sup>cdk4</sup> ). Cyclin-dependent kinases (cdk) are the catalytic subunits of the cyclin/cdk complexes, which phosphorylate substrates on threonine/serine residues. Cdk4 associates with the D-type cyclins and is important in the progression of cells from the G <sub>1</sub> -phase to the S-phase of the cell cycle. This antibody does not cross-react with other members of the cdk family.
<b>Species Reactivity:</b>	Human, mouse, and rat cdk4 protein. Other species were not tested.
<b>Applications:</b>	This antibody is suitable for use in immunoprecipitation (co-precipitates cyclin D; unbound cdk), Western blotting, immunofluorescence.
<b>Suggested Working Dilutions:</b>	For immunoprecipitation, use 2µg/mg of protein lysate; for Western blotting, 1-2 µg/mL is recommended; and for immunohistochemistry.
<b>Recommended Positive Control:</b>	MAD109, LS174T, or PC12 cells.
<b>Storage:</b>	Store at 2-8°C.
<b>Expiration Date:</b>	Expires one year from date of receipt when stored as instructed.
<b>References:</b>	Depoortere, F., <i>et al.</i> (1998) A requirement for cyclin D3-cyclin-dependent kinase (cdk)-4 assembly in the cyclic adenosine monophosphate-dependent proliferation of thymocytes. <i>The Journal of Cell Biology</i> 140(6):1427-1439. Jadayel, D.M., <i>et al.</i> (1997) Potential role for concurrent abnormalities of the cyclin D1, p16 <sup>CDKN2</sup> and p15 <sup>CDKN2B</sup> genes in certain B cell non-Hodgkin's lymphomas. Functional studies in a cell line (Granta 519). <i>Leukemia</i> 11:64-72.

**For research use only. CAUTION: Not intended for human or animal therapeutic or diagnostic use.**

[www.invitrogen.com](http://www.invitrogen.com)

Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288 • E-mail: [techsupport@invitrogen.com](mailto:techsupport@invitrogen.com)

PI AHZ0202

(Rev 12/09) DCC-09-2077

**Important Licensing Information** - These products may be covered by one or more Limited Use Label Licenses (see the Invitrogen Catalog or our website, [www.invitrogen.com](http://www.invitrogen.com)). By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.